Nektar Therapeutics (NKTR) Now Covered by Piper Jaffray

Joanna Estrada
April 16, 2018

About 1.02 million shares traded. Finally, Slow Capital Inc. purchased a new position in Nektar Therapeutics in the fourth quarter valued at about $919,000. We have taken technical analysis of Nektar Therapeutics (NKTR)'s stock recent trading price and 3 moving average price of updated past trading days (20, 50 and 200). About 1.08 million shares traded.

HC Wainwright set a $125.00 price objective on Nektar Therapeutics (NASDAQ:NKTR) in a report released on Monday morning. It has outperformed by 335.46% the S&P500.The move comes after 6 months negative chart setup for the $16.17B company. Adage Cap Gp Ltd, a Massachusetts-based fund reported 139,000 shares. The stock decreased 2.64% or $2.74 during the last trading session, reaching $101. About 5.92 million shares traded.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, March 1st. It has outperformed by 25.88% the S&P500. J.P. Morgan maintained Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, July 18 with "Buy" rating. The positive are 100%.

In 2017Q4 SEC form is reported Rice Hall James & Associates Llc's stake in Nektar Therapeutics (NKTR) which was decreased by 16.81%. SunTrust maintained the stock with "Hold" rating in Thursday, November 9 report. BidaskClub downgraded shares of Nektar Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 8th. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.20. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. The company was maintained on Tuesday, May 30 by Roth Capital. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Monday, November 13. The firm presently has a "buy" rating on the biopharmaceutical company's stock. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Aegis Capital has "Buy" rating and $2700 target. Jefferies Group increased their target price on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a "buy" rating in a research note on Tuesday, January 16th. During the same period past year, the firm earned ($0.28) EPS.

Nektar Therapeutics (NKTR) held 173.90 million outstanding shares now. It also upped Hartford Finl Svcs Group Inc (NYSE:HIG) stake by 163,191 shares and now owns 1.76 million shares.

Since December 13, 2017, it had 0 insider buys, and 11 sales for $40.88 million activity.

Shares of Nektar Therapeutics stock traded down $1.00 on Friday, hitting $103.01. Moreover, Arizona State Retirement has 0.15% invested in Nektar Therapeutics (NASDAQ:NKTR). Another trade for 2,545 shs valued at $211,082 was made by Thomsen Jillian B. on Friday, February 16. Comerica National Bank accumulated 0.08% or 161,656 shares. $238,453 worth of stock was sold by Hora Maninder on Friday, February 16.

If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. That's change of 0.21, from 2017Q3's 1.4. It is negative, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 54 grew positions while 65 funds amassed positions. The investment professionals in our partner's database reported: 150.36 million shares, up from 148.76 million shares in 2017Q3.

Weekly, Monthly, Quarterly And Six-Month Performance: Taking a look at the performance of JBLU stock, an investor will come to know that the weekly performance for this stock valued at -5.28%, resulting in a performance for the month at -12.53%. Manufacturers Life Ins The holds 0.01% or 112,452 shares in its portfolio. State Of Wisconsin Inv Board owns 147,000 shares. American International Group Inc. now owns 118,366 shares of the biopharmaceutical company's stock worth $2,841,000 after purchasing an additional 6,476 shares during the period. Paradigm Asset Limited Liability Corp has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). It is positive, as 78 investors sold CTL shares while 110 reduced holdings. Following the transaction, the chief executive officer now owns 333,268 shares in the company, valued at approximately $25,268,379.76. West Family holds 10.86% or 2.54M shares. Finally, Cowen reissued a "buy" rating and issued a $101.00 price target on shares of Nektar Therapeutics in a research note on Friday, March 2nd. Coldstream Capital reported 6,898 shares. Cambridge Research Advsr accumulated 3,666 shs. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action. Schwab Charles Invest Management Inc has invested 0.04% in Nektar Therapeutics (NASDAQ:NKTR).

Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on April, 26. HPT's profit will be $156.13 million for 6.62 P/E if the $0.95 EPS becomes a reality. After having $-0.14 EPS previously, Nektar Therapeutics's analysts see 207.14% EPS growth. Analysts are turning out to be more optimistic than before, with 5 of analysts who cover Seagate Technology plc (NASDAQ:STX) advice adding it to buy candidate list. The firm has "Buy" rating by Jefferies given on Wednesday, August 16. The company now has a consensus rating of Buy and a consensus target price of $66.91.

Other reports by Click Lancashire

Discuss This Article